Citalopram in mentally retarded patients with depression: a long-term clinical investigation

European Psychiatry : the Journal of the Association of European Psychiatrists
W M VerhoevenS Tuinier

Abstract

The effect of citalopram was investigated in 20 mentally retarded patients suffering from a depressive disorder characterized by alterations in the domains of affectivity, motivation, motor activity and vital signs. The study followed a baseline-controlled open design. Citalopram was started in a daily dosage of 20 mg that was kept unchanged for 6 weeks. Thereafter dosage was adjusted to maximally 60 mg per day. Treatment effects were assessed according to the Clinical Global Improvement Scale (CGIS) after at least 6 months. In 12 of the 20 patients a moderate to marked improvement in all domains was observed upon treatment with 20-40 mg citalopram daily. Treatment for one year in the effective dose prevented recurrence of depressive symptomatology. Concomitant use of sedative anticonvulsants reduced responsiveness to treatment. No interactions were observed. It is concluded that citalopram is a well-tolerated, safe and effective antidepressant in mentally retarded subjects with depressive disorders.

References

Jan 1, 1986·Community Mental Health Journal·F J MenolascinoA S Levitas
Mar 1, 1986·Comprehensive Psychiatry·B A Myers
Apr 1, 1980·Archives of General Psychiatry·M A Test, L I Stein
Jul 1, 1995·Research in Developmental Disabilities·B A Myers, S M Pueschel
Apr 1, 1995·Clinical Dysmorphology·J Turk, P Hill
Feb 1, 1995·Journal of Intellectual Disability Research : JIDR·W Meins
Sep 1, 1993·Research in Developmental Disabilities·M Fujiki, B Brinton
Mar 1, 1996·International Clinical Psychopharmacology·C G Gottfries
Jun 1, 1996·Journal of Intellectual Disability Research : JIDR·W Meins
Jan 1, 1997·The Journal of International Medical Research·E K SyvälahtiR K Salokangas
Jan 16, 1998·Journal of Intellectual Disability Research : JIDR·G M MarstonA Roy
Feb 26, 1998·International Clinical Psychopharmacology·C G Gottfries
May 23, 1998·Neuropsychobiology·H M van Praag
Oct 3, 1999·Journal of Clinical Psychopharmacology·S L RasmussenP Tanghøj
Feb 9, 2000·The Journal of Clinical Psychiatry·L FranchiniE Smeraldi
Jan 1, 1997·European Psychiatry : the Journal of the Association of European Psychiatrists·S P McKenna

❮ Previous
Next ❯

Citations

Aug 30, 2008·The Psychiatric Quarterly·Thaddeus P Ulzen, Richard E Powers
Aug 30, 2008·The Psychiatric Quarterly·Diana J Antonacci, Nadir Attiah
Aug 26, 2006·Journal of Child Psychology and Psychiatry, and Allied Disciplines·Benjamin L Handen, Richard Gilchrist
May 27, 2014·Journal of Neural Transmission·Frank HäβlerOlaf Reis
Jan 19, 2016·Current Opinion in Psychiatry·Na Young Ji, Robert L Findling
May 26, 2018·Journal of Intellectual Disability Research : JIDR·P C M HamersH Hermans
Jul 1, 2003·Paediatrics & Child Health·Jean-François LemayA Micheil Innes
Feb 2, 2021·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Temitope OgundareDavid C Henderson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.